




MOLECULAR TARGETING TECHNOLOGIES, INC.

Translating Novel Technologies into Tomorrow's Medicines


FGA

¹⁸F-Fluoroglucuric Acid (FGA) for
necrosis: stroke imaging

A. HMPAO



B. FGA



C. TTC Stain



Challenges

Seeing drug response in cancer treatment takes weeks, negatively affecting outcomes.

Solution

Imaging cancer/acute MI necrosis with radiolabeled glucuric acid delivers actionable diagnostic results in one day.

Tech

- FGA effectively labels and images necrosis.
- Three likely mechanisms identified

Proof of Concept

- FGA (¹⁸F - Fluoroglucuric Acid) & TGA (^{99m}Tc - glucarate) easily detect stroke and acute MI.
- TGA was safe and effective for rapid, early detection of acute MI and cancer (breast, esophagus, head-and neck, and SCLC and NSCLC lung cancers) in clinical studies.

Funding

- MTT Holding Co. financing

Next - FGA

- Preclinical validation & IND enabling
- cGMP manufacture
- Clinical trials

MTTI

Molecular Targeting Technologies, Inc. is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases.

Two radiotherapeutics and two radiodiagnostics lead our 10 asset pipeline.

Contact: cpak@mtarget.com

More information: www.mtarget.com.

A simple, efficient, proprietary route to FGA

